Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy

Despite the efficacy of the on-demand treatment for the control of acute attacks of Hereditary Angioedema due to C1-Inhibitor Deficiency (C1-INH-HAE), the number and severity of attacks and the impairment in the quality of life of the affected patients have led to the development of a new monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales: Bova, Maria, Valerieva, Anna, Wu, Maddalena Alessandra, Senter, Riccardo, Perego, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815761/
https://www.ncbi.nlm.nih.gov/pubmed/31695331
http://dx.doi.org/10.2147/DDDT.S192475
_version_ 1783463243017093120
author Bova, Maria
Valerieva, Anna
Wu, Maddalena Alessandra
Senter, Riccardo
Perego, Francesca
author_facet Bova, Maria
Valerieva, Anna
Wu, Maddalena Alessandra
Senter, Riccardo
Perego, Francesca
author_sort Bova, Maria
collection PubMed
description Despite the efficacy of the on-demand treatment for the control of acute attacks of Hereditary Angioedema due to C1-Inhibitor Deficiency (C1-INH-HAE), the number and severity of attacks and the impairment in the quality of life of the affected patients have led to the development of a new monoclonal antibody, lanadelumab, directly addressed to the blockage of bradykinin, the principal mediator of vasodilation during angioedema attacks. It is indicated for the prophylactic treatment, it is easy to administer, highly effective and with known limited side effects. The current review summarizes the development of the drug, its clinical background and its perspectives.
format Online
Article
Text
id pubmed-6815761
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68157612019-11-06 Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy Bova, Maria Valerieva, Anna Wu, Maddalena Alessandra Senter, Riccardo Perego, Francesca Drug Des Devel Ther Review Despite the efficacy of the on-demand treatment for the control of acute attacks of Hereditary Angioedema due to C1-Inhibitor Deficiency (C1-INH-HAE), the number and severity of attacks and the impairment in the quality of life of the affected patients have led to the development of a new monoclonal antibody, lanadelumab, directly addressed to the blockage of bradykinin, the principal mediator of vasodilation during angioedema attacks. It is indicated for the prophylactic treatment, it is easy to administer, highly effective and with known limited side effects. The current review summarizes the development of the drug, its clinical background and its perspectives. Dove 2019-10-22 /pmc/articles/PMC6815761/ /pubmed/31695331 http://dx.doi.org/10.2147/DDDT.S192475 Text en © 2019 Bova et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Bova, Maria
Valerieva, Anna
Wu, Maddalena Alessandra
Senter, Riccardo
Perego, Francesca
Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
title Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
title_full Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
title_fullStr Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
title_full_unstemmed Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
title_short Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
title_sort lanadelumab injection treatment for the prevention of hereditary angioedema (hae): design, development and place in therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815761/
https://www.ncbi.nlm.nih.gov/pubmed/31695331
http://dx.doi.org/10.2147/DDDT.S192475
work_keys_str_mv AT bovamaria lanadelumabinjectiontreatmentforthepreventionofhereditaryangioedemahaedesigndevelopmentandplaceintherapy
AT valerievaanna lanadelumabinjectiontreatmentforthepreventionofhereditaryangioedemahaedesigndevelopmentandplaceintherapy
AT wumaddalenaalessandra lanadelumabinjectiontreatmentforthepreventionofhereditaryangioedemahaedesigndevelopmentandplaceintherapy
AT senterriccardo lanadelumabinjectiontreatmentforthepreventionofhereditaryangioedemahaedesigndevelopmentandplaceintherapy
AT peregofrancesca lanadelumabinjectiontreatmentforthepreventionofhereditaryangioedemahaedesigndevelopmentandplaceintherapy

Ejemplares similares